SQUAWK/NEWS
Account
Theme
Account
Menu
Live News NEWS FLASH L impact

Novartis: Pelabresib Shows Sustained Effects At 144 Weeks In Phase III First-Line Myelofibrosis Trial

Six-Year Kisqali NATALEE Analysis Adds Data In HR+/HER2- Early Breast Cancer - SABCS To Feature NATALEE Nodal Analysis And First Phase I/II RAE346 Results In HR+/HER2- Breast Cancer

Related stories